(Q46058355)

19 December 2017

title

PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma (English)

1 reference

19 December 2017

author

Andreas K. Buck

4

1 reference

19 December 2017

author name string

Heribert Hänscheid

1

1 reference

19 December 2017

Reinhart A Sweeney

2

1 reference

19 December 2017

Michael Flentje

3

1 reference

19 December 2017

Mario Löhr

5

1 reference

19 December 2017

Samuel Samnick

6

1 reference

19 December 2017

Michael Kreissl

7

1 reference

19 December 2017

Frederik A Verburg

8

1 reference

19 December 2017

publication date

20 April 2012

1 reference

19 December 2017

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

19 December 2017

volume

39

1 reference

19 December 2017

issue

8

1 reference

19 December 2017

page(s)

1284-1288

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s00259-012-2124-x

exact match

0 references

cites work

Medical therapies for meningiomas

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2124-X

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22526964

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22526964

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00259-012-2124-X

1 reference

19 December 2017

1 reference

19 December 2017